However, when compared to other HR-deficient mCRPCs, the CDK12-abberant tumours were found to be transcriptionally, genetically and phenotypically different (88) and displayed more aggressive clinical behaviour (including higher Gleason scores at presentation, a shorter time to metastasis and CRPC) (121). This evidence concerns the gene CDK12 and neoplasm.